Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lu-177-PSMA-617 in Low Volume Metastatic Prostate Cancer
NCT03828838Phase 2Completed
- Sponsor
- Radboud University Medical Center
- Start
- Jul 2018
- Primary completion
- Nov 2019
- Modality
- Small Molecules, Peptide-Drug Conjugates
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of lutetium lu 177 vipivotide tetraxetan in prostate cancer (PCa), sponsored by Radboud University Medical Center. Primary endpoints: Doses delivered to the tumors in Cycle 1 at 56 days, Doses delivered to the tumors in Cycle 2 at 56 days and 2 more. Started Jul 2018; status: completed.
02
Drugs
lutetium lu 177 vipivotide tetraxetan
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NCT03828838.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03828838.